JP5945554B2 - 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター） - Google Patents

縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター） Download PDF

Info

Publication number
JP5945554B2
JP5945554B2 JP2013555597A JP2013555597A JP5945554B2 JP 5945554 B2 JP5945554 B2 JP 5945554B2 JP 2013555597 A JP2013555597 A JP 2013555597A JP 2013555597 A JP2013555597 A JP 2013555597A JP 5945554 B2 JP5945554 B2 JP 5945554B2
Authority
JP
Japan
Prior art keywords
pentalene
diaza
tetrahydro
oxy
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2013555597A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014506602A (ja
JP2014506602A5 (enExample
Inventor
アンソニー シー． ブラックバーン，
アンソニー シー． ブラックバーン，
サンドン ハン，
サンドン ハン，
ロバート エム． ジョンズ，
ロバート エム． ジョンズ，
アントニオ ガリド モンタルバン，
アントニオ ガリド モンタルバン，
バイマン ビー． パル，
バイマン ビー． パル，
ジェイミー カリン ロイター，
ジェイミー カリン ロイター，
Original Assignee
アリーナ ファーマシューティカルズ， インコーポレイテッド
アリーナ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アリーナ ファーマシューティカルズ， インコーポレイテッド, アリーナ ファーマシューティカルズ， インコーポレイテッド filed Critical アリーナ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2014506602A publication Critical patent/JP2014506602A/ja
Publication of JP2014506602A5 publication Critical patent/JP2014506602A5/ja
Application granted granted Critical
Publication of JP5945554B2 publication Critical patent/JP5945554B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2013555597A 2011-02-25 2012-02-24 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター） Expired - Fee Related JP5945554B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161446732P 2011-02-25 2011-02-25
US61/446,732 2011-02-25
US201161448542P 2011-03-02 2011-03-02
US61/448,542 2011-03-02
PCT/US2012/026506 WO2012116276A1 (en) 2011-02-25 2012-02-24 Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)

Publications (3)

Publication Number Publication Date
JP2014506602A JP2014506602A (ja) 2014-03-17
JP2014506602A5 JP2014506602A5 (enExample) 2015-04-16
JP5945554B2 true JP5945554B2 (ja) 2016-07-05

Family

ID=45841624

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013555597A Expired - Fee Related JP5945554B2 (ja) 2011-02-25 2012-02-24 縮合型アザ環の結晶形およびその調製プロセス（カンナビノイド受容体モジュレーター）

Country Status (20)

Country Link
US (4) US9458136B2 (enExample)
EP (3) EP4166552B1 (enExample)
JP (1) JP5945554B2 (enExample)
KR (1) KR102036932B1 (enExample)
CN (1) CN103608343B (enExample)
AU (1) AU2012222146B2 (enExample)
BR (1) BR112013021549B1 (enExample)
CA (1) CA2827057C (enExample)
CL (1) CL2013002436A1 (enExample)
CO (1) CO6852066A2 (enExample)
DK (1) DK3395812T3 (enExample)
EA (1) EA035989B1 (enExample)
ES (1) ES2932441T3 (enExample)
IL (1) IL227782A (enExample)
MX (1) MX346533B (enExample)
MY (1) MY165767A (enExample)
PH (1) PH12013501726A1 (enExample)
SG (1) SG192817A1 (enExample)
WO (1) WO2012116276A1 (enExample)
ZA (1) ZA201306402B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ598288A (en) 2009-08-28 2014-02-28 Arena Pharm Inc Cannabinoid receptor modulators
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
ES2929977T3 (es) 2011-02-25 2022-12-05 Arena Pharm Inc Moduladores del receptor cannabinoide
CA2827057C (en) 2011-02-25 2022-06-07 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
WO2016085941A1 (en) * 2014-11-25 2016-06-02 Arena Pharmaceuticals, Inc. Processes for the preparation of cannabinoid receptor modulators
UA124626C2 (uk) * 2016-04-10 2021-10-20 Арена Фармасьютікалз, Інк. СПОСОБИ ЛІКУВАННЯ СЕЛЕКТИВНИМИ АГОНІСТАМИ РЕЦЕПТОРА СВ<sub>2</sub>
KR20200005614A (ko) 2017-05-08 2020-01-15 아레나 파마슈티칼스, 인크. 내장 통증의 치료를 위한 화합물 및 방법
WO2018208847A1 (en) 2017-05-08 2018-11-15 Arena Pharmaceuticals, Inc. Compounds and methods for treatment of pain from inflammatory bowel disease
CN114391011A (zh) * 2019-09-12 2022-04-22 四川海思科制药有限公司 一种六氢化苯并吡唑衍生物及其制备
WO2023059610A1 (en) 2021-10-05 2023-04-13 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of cannabinoid receptor modulators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3964478B2 (ja) 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
IL145922A0 (en) 1999-04-28 2002-07-25 Aventis Pharma Gmbh Di-aryl acid derivatives as ppar receptor ligands
US20040259936A1 (en) 2001-12-07 2004-12-23 Nagarkatti Leonard C Treatment of neoplasia
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
WO2006025069A2 (en) 2004-07-12 2006-03-09 Cadila Healthcare Limited Tricyclic pyrazole derivatives as cannabinoid receptor modulators
FR2875230A1 (fr) * 2004-09-13 2006-03-17 Sanofi Aventis Sa Derives de pyrazole condense, leur preparation et leur application en therapeutique
DE102004054666A1 (de) 2004-11-12 2006-05-18 Bayer Cropscience Gmbh Substituierte Pyrazol-3-carboxamide, Verfahren zur Herstellung und Verwendung als Herbizide und Pflanzenwachstumsregulatoren
PE20060949A1 (es) 2004-12-23 2006-10-11 Arena Pharm Inc Derivados fusionados de pirazol como agonistas del receptor de niacina
CN101238107A (zh) * 2005-06-02 2008-08-06 格兰马克药品股份有限公司 新的大麻素受体配体，含有该配体的药物组合物及其制备方法
EP1902034B1 (en) * 2005-06-02 2011-03-30 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
EA200970080A1 (ru) 2006-07-04 2009-06-30 Янссен Фармацевтика Нв Бензимидазольные агонисты каннабиноидов, содержащие замещенную гетероциклическую группу
JP5030114B2 (ja) 2006-09-25 2012-09-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体をモジュレートする化合物
US8481574B2 (en) 2006-10-12 2013-07-09 Abbott Laboratories Compounds as cannabinoid receptor ligands
US7928103B2 (en) 2006-10-17 2011-04-19 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
CA2668491A1 (en) 2006-11-03 2008-05-08 Glenmark Pharmaceuticals S.A. Novel cannabinoid receptor ligands, pharmaceutical compositions containing them, and processes for their preparation
WO2008064054A2 (en) 2006-11-21 2008-05-29 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
WO2008079316A1 (en) 2006-12-20 2008-07-03 Cara Therapeutics, Inc. Tetrahydroquinolinones, tetrahydronaphthyridones and derivatives thereof
WO2008085302A1 (en) 2006-12-20 2008-07-17 Merck & Co., Inc. Imidazopyridine analogs as cb2 receptor modulators, useful in the treatment of pain, respiratory and non-respiratory diseases
US20080214537A1 (en) 2007-03-02 2008-09-04 Cara Therapeutics, Inc. Bridged phenanthridines
JP5185924B2 (ja) 2007-03-16 2013-04-17 京セラ株式会社 誘電体磁器およびコンデンサ
ES2548764T3 (es) 2007-03-30 2015-10-20 Janssen Pharmaceutica N.V. Agonistas de cannabinoides de bencimidazol
US20090209536A1 (en) 2007-06-17 2009-08-20 Kalypsys, Inc. Aminoquinazoline cannabinoid receptor modulators for treatment of disease
BRPI0812504B8 (pt) 2007-06-21 2021-05-25 Cara Therapeutics Inc composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
US8338623B2 (en) 2007-07-09 2012-12-25 Abbvie Inc. Compounds as cannabinoid receptor ligands
US7943658B2 (en) 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
WO2009025785A2 (en) 2007-08-21 2009-02-26 Merck & Co., Inc. Cb2 receptor ligands for the treatment of pain
UA104010C2 (en) 2008-12-18 2013-12-25 Эли Лилли Энд Компани Purine compounds
WO2010088050A2 (en) 2009-01-28 2010-08-05 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
NZ598288A (en) * 2009-08-28 2014-02-28 Arena Pharm Inc Cannabinoid receptor modulators
CA2827057C (en) 2011-02-25 2022-06-07 Arena Pharmaceuticals, Inc. Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
ES2929977T3 (es) * 2011-02-25 2022-12-05 Arena Pharm Inc Moduladores del receptor cannabinoide
US9597340B2 (en) 2011-02-25 2017-03-21 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators
WO2012116278A1 (en) 2011-02-25 2012-08-30 Arena Pharmaceuticals, Inc. Cannabinoid receptor modulators

Also Published As

Publication number Publication date
CA2827057C (en) 2022-06-07
US20170144993A1 (en) 2017-05-25
EP3395812B1 (en) 2022-09-28
NZ614787A (en) 2014-08-29
EP4166552B1 (en) 2025-03-19
EA201391233A1 (ru) 2014-02-28
EP4166552A1 (en) 2023-04-19
BR112013021549A2 (pt) 2016-11-01
IL227782A0 (en) 2013-09-30
US20140135345A1 (en) 2014-05-15
PH12013501726A1 (en) 2014-01-13
JP2014506602A (ja) 2014-03-17
CL2013002436A1 (es) 2014-01-24
CN103608343B (zh) 2019-02-01
ES2932441T3 (es) 2023-01-19
US9458136B2 (en) 2016-10-04
MY165767A (en) 2018-04-23
AU2012222146A1 (en) 2013-09-19
MX346533B (es) 2017-03-14
MX2013009760A (es) 2014-06-11
CN103608343A (zh) 2014-02-26
US10183930B2 (en) 2019-01-22
IL227782A (en) 2017-02-28
AU2012222146B2 (en) 2017-05-11
US20210380560A1 (en) 2021-12-09
DK3395812T3 (da) 2022-11-28
KR102036932B1 (ko) 2019-10-25
KR20140025353A (ko) 2014-03-04
US11560369B2 (en) 2023-01-24
BR112013021549B1 (pt) 2022-01-11
CA2827057A1 (en) 2012-08-30
EP3395812A1 (en) 2018-10-31
WO2012116276A1 (en) 2012-08-30
CO6852066A2 (es) 2014-01-30
US20190308952A1 (en) 2019-10-10
EP3395812B8 (en) 2022-11-02
US10981895B2 (en) 2021-04-20
EP2678330A1 (en) 2014-01-01
SG192817A1 (en) 2013-09-30
EA035989B1 (ru) 2020-09-09
ZA201306402B (en) 2022-03-30

Similar Documents

Publication Publication Date Title
US11560369B2 (en) Crystalline forms and processes for the preparation of cannabinoid receptor modulators
TWI503316B (zh) 類大麻酚受體調節劑
DE69425662T2 (de) Als heilmittel nutzbare piperazin verbindungen
JP2008504276A (ja) アミド化合物およびその医薬としての使用
JP2009535420A (ja) １１−βヒドロキシルステロイドデヒドロゲナーゼタイプ１のモジュレーターとしてのテトラ置換ウレア
CN103012378A (zh) 作为5-ht2a血清素受体调节剂适用于治疗与其相关的病症的3-苯基-吡唑衍生物
HK1263040A1 (en) Crystalline forms and processes for the preparation of condensed azacycles (cannabinoid receptor modulators)
NZ614787B2 (en) Crystalline forms and processes for the preparation of condensed azacycles ( cannabinoid receptor modulators)
JPH07252218A (ja) ピロリジノン誘導体
WO2016085941A1 (en) Processes for the preparation of cannabinoid receptor modulators
JP2010539214A (ja) カンナビノイドｃｂ１受容体アゴニストとしての５−アリール−４，５−ジヒドロ−（１ｈ）−ピラゾール

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150220

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20150903

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20150929

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160316

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160502

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160530

R150 Certificate of patent or registration of utility model

Ref document number: 5945554

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees